1 Markers of psoriatic skin phenotype: androgen/estrogen and cortisone/cortisol

- 2 imbalance, and DNA damage
- 3

4 Şeyma Başar Kılıç¹, Serpil Taheri^{2, 3}, Ecmel Mehmetbeyoğlu³, Eda Öksüm Solak⁴, Minoo
5 Rassoulzadegan³ and Murat Borlu⁵,

6 Author names and affiliations

⁷ ¹Şeyma Başar Kılıç,MD, Aksaray University Training and Research Hospital, Dermatology

- 8 and Venereology Department, Aksaray, Turkey. Email:drseymabasar@gmail.com
- ⁹ ² Serpil Taheri, Erciyes University, Medical Scholl, Medical Biology Department, Kayseri,
- 10 Turkey. Email address:serpiltaheri@hotmail.com
- ¹¹ ³Ecmel Mehmetbeyoglu, Betul Ziya Eren Genome and Stem Cell Center, Erciyes University,
- 12 Kayseri, Turkey Email address: mehmetbeyogluse@cardiff.ac.uk
- ⁴Eda Öksüm Solak, Erciyes University Medical School, Dermatology and Venereology
- 14 Department, Kayseri, Turkey Email address:eoksum@hotmail.com
- ³ Minoo Rassoulzadegan, Betul Ziya Eren Genome and Stem Cell Center, Erciyes University,
- 16 Kayseri, Turkey Email address: Minoo.RASSOULZADEGAN@univ-cotedazur.fr
- ⁵Murat Borlu, Erciyes University, Medical School, Dermatology and Venereology
- 18 Department, Kayseri, Turkey Email address:murat_borlu@hotmail.com
- 19 **Running title:** Androgens and DNA damage in psoriatic skin formation
- **20 Word Count: 3330**
- 21 Number of Tables:4
- 22 Number of figures: 3
- 23 Ethical approval: Erciyes University Ethics committee no: 2019/121
- 24 Financial support: Supported by the Erciyes University Research Projects Unit. Project no:
- 25 TCD-2019-9240
- 26 **Corresponding Author**: Murat Borlu, MD NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

27 Erciyes University, Dermatology and Venereology Department, Kayseri, Turkey. Email

- 28 address: murat_borlu@hotmail.com
- 29 Phone number: +90 5054845106

30 ABSTRACT

Patients prone to psoriasis suffer after a breakdown of the epidermal barrier and developpoorly healing lesions with abnormal proliferation of keratinocytes.

Strong inflammatory reactions with genotoxicity (short telomeres) suggest impaired immune defences with DNA damage repair response (DDR) in patients with psoriasis. Recent evidence indicates the existence of crosstalk mechanisms linking the DDR machinery and hormonal signalling pathways that cooperate to influence both progressions of many diseases and responses to treatment.

The aim of this study was to clarify whether steroid biosynthesis and genomic stability markers are altered in parallel during the formation of psoriatic skin. Understanding between the interaction of the steroid pathway and DNA damage response is crucial to addressing underlying fundamental issues and managing resulting epidermal barrier disruption in psoriasis.

Twenty patients with psoriasis and fifteen healthy volunteers were included in this study. 43 Transcription levels of estrogen ESR2). 44 (ESR1.androgen (AR),glucocorticoid/mineralocorticoid receptors (NR3C1, NR3C2), HSD11B1/HSD11B2 genes, and 45 DNA damage sensors (SMC1A, TREX1, TREX2, SSBP3, RAD1, RAD18, EXO1, POLH, 46 HUS1) were determined by Real-Time-PCR in blood and skin samples (Lesional, non-47 48 lesional) from psoriasis and control groups.

Results: We found that *ESR1*, *ESR2*, *HSD11B1*, *NR3C1*, *NR3C2*, *POLH*, and *SMC1A*transcripts were significantly decreased and *AR*, *TREX1*, *RAD1*, and *SSBP3* transcripts were
increased dramatically in the lesional skin compared to skin samples of controls.

As a result, we found that the regulation of the steroidogenic pathway was disrupted in the lesional tissue of psoriasis patients and that a sufficient glucocorticoid and mineralocorticoid response did not form and the estrogen/androgen balance was altered in favour of androgens. We suggest that an increased androgen response in the presence of DDR increases the risk of developing psoriasis. Although this situation may be the cause or the consequence of a disruption of the epidermal barrier, our data suggest developing new therapeutic strategies. **Keywords:** Psoriasis, Steroidogenic pathway, Genome integrity, Transcript profiles,

59

60

61 **INTRODUCTION**

Psoriasis is a chronic and recurrent inflammatory skin disease characterized by abnormal 62 keratinocyte proliferation, vascular hyperplasia, and inflammatory cell infiltration in the 63 dermis and epidermis. Disruption of the integrity or function of the epidermal barrier leads to 64 epidermal hyperplasia and psoriasis [1,2]. It is generally accepted that the central 65 pathogenesis of psoriasis is the dysfunction of T lymphocytes cells affected by complex 66 interactions between genetic and environmental factors such as trauma, infection, stress, 67 medications, smoking and alcohol consumption [3,4]. It has been revealed that TNF-alpha, 68 interleukin 23, 17 and 22 play a major role, resulting from the main interaction of epidermal 69 dendritic cells, T lymphocytes and keratinocyte cells. However, it is unclear what determines 70 dendritic cell stimulation and T lymphocyte cells differentiation. 71

There are many complex immunological reactions in psoriasis resulting in epidermal hyperproliferation with abnormal keratinocyte differentiation [5]. However, it is not yet known what triggers this mechanism, whether the inflammation that occurs with the breakdown of the epidermal barrier induces the proliferation of keratinocyte or the accumulated damage on

the DNA of keratinocytes triggers the inflammation. Revealing which features of theepidermal barrier make up this cascade may explain parts of the disease that are still unclear.

Psoriasis has a family heritage, but so far no genes or mutations have been identified that could fully explain the mechanism of the disease. The disease affects both men and women. The skin is considered the extra-adrenal organ that plays an important role in the neuroendocrine-immune system by synthesizing a wide range of hormones from cholesterol to glucocorticoids and sex steroids [6]. It is important to maintain the regulation of lipids, cholesterol, ceramide, and epidermal DNA synthesis in the skin in order to preserve the integrity of the epidermal barrier [7–9].

The synthesis of steroid in the skin is very important for the maintenance of the epidermal 85 barrier function. While a sufficient estrogen response ensures the moisture balance of the skin, 86 87 testosterone plays the opposite role and its increase triggers the deterioration of the epidermal barrier [9–12]. Additionally, the balance of 11β -hydroxysteroid dehydrogenase type 1 88 (HSD11B1) and 11β-hydroxysteroid dehydrogenase type 2 (HSD11B2) enzymes, which 89 convert active cortisol/inactive cortisone, is also very important for healthy skin. Increased or 90 insufficient levels of glucocorticoid or their receptor responses (Glucocorticoid Receptor 91 92 (NR3C1), Mineralocorticoid Receptor (NR3C2)) can also impair skin barrier function [8,13,14]. Disruption of epidermal barrier integrity and regulation of epidermal DNA 93 94 synthesis also triggers the DNA damage response [7]. We have recently shown that the 95 integrity of the genome is altered in patients predisposed to develop psoriasis [15].

We hypothesize that disruption of local regulation of steroidogenic activity is a threat to the integrity of the epidermal barrier that triggers DNA damage. The inability to sufficiently repair and the DNA fragments that occur during the repair of the damage trigger the immune system and cause inflammation. Finally, when DNA damage is not sufficiently repaired, cell

proliferation altered. We sought to identify transcripts associated with disruption of the
 epidermal barrier, causing DNA damage and disrupting local steroidogenic activity in patients
 with psoriasis.

Revealing the features of the epidermal barrier that make up this cascade may explain parts of
the disease that are unclear [16]. We determined the transcript levels of *estrogen (ESR1, ESR2), androgen (AR), glucocorticoid/mineralocorticoid receptors (NR3C1, NR3C2), HSD11B1/ HSD11B2* genes and *DNA damage sensors (SMC1A, TREX1, TREX2, SSBP3, RAD1, RAD18 EXO1, POLH, HUS1*) in the lesional and non-lesional skin tissue according to
healthy skin. We reveal an imbalance of androgen/estrogen and cortisol/cortisone, as well as
an increased response to DNA damage by a psoriatic skin phenotype.

110

111 MATERIALS AND METHODS

This study was approved by the Human Ethics Committee of the Ercives University on 112 20/02/2019, with the decision number 2019/121, and 20 patients who were diagnosed with 113 chronic plaque-type psoriasis and admitted at the Ercives University, Faculty of Medicine, 114 Department of Dermatology and Venereal Diseases and age- and sex-matched 15 healthy 115 volunteers without chronic disease were included after obtaining their consent. The patients 116 117 and controls participating in the study were verbally informed and their written consent was 118 obtained. Patients under the age of 18 and healthy controls were not included in the study. Psoriasis Area Severity Index (PASI) values were calculated [17] and recorded and patients 119 with a PASI value greater than 10 were included in the study. Patients with an 120 121 inflammatory/autoimmune or chronic disease other than psoriasis and patients who have received topical therapy for psoriasis within the last 2 weeks or systemic therapy in the last 4 122 weeks were not included in the study. 123

124 Collection of skin biopsy and blood samples from psoriasis patients and healthy control125 groups:

Skin samples were taken from the lesional skin and normal skin adjacent to the lesion from 126 the 20 patients with psoriasis. Skin biopsy samples were taken from skin areas (popliteal 127 fossa) located behind the knee of the healthy control group who accepted to participate in the 128 study. When collecting skin biopsy samples, local anesthesia was applied under the skin, and 129 tissue samples were taken with a 3 mm puncture tool after providing completely sterile 130 131 conditions. In addition, 5 ml of peripheral venous blood was collected from patients and study control groups in a purple-capped EDTA tube. Tissue and blood samples were immediately 132 delivered to the Genome and Stem Cell Center Genome Unit, RNA isolations were performed 133 immediately, and RNA samples were stored at -80°C until at the start of the study. 134

135 RNA isolation and Real -Time PCR

136 Total RNA was isolated from skin tissue and blood samples using TRIzol (Cat No: 11667165001 Roche, Germany and cDNA was synthesized from RNA samples obtained 137 using a cDNA synthesis kit (Cat no:18091200, Thermo Fisher Scientific, USA). cDNA 138 samples were quantified using the BioMark high-throughput Real-Time PCR system 139 (Fluidigm, San Francisco, CA) for Q-PCR analysis at transcript levels [18,19]. We selected 140 sixteen candidate transcripts known to be involved in DNA damage and repair ((Structural 141 Maintenance Of Chromosomes 1A (SMC1A), Three Prime Repair Exonuclease 1(TREX1), 142 Three Prime Repair Exonuclease 2 (TREX2), Single Stranded DNA Binding Protein 3 143 144 (SSBP3), RAD1 Checkpoint DNA Exonuclease (RAD1), RAD 18 E3 Ubiquitin Protein Ligase (RAD18), Exonuclease 1 (EXO1), DNA Polymerase Eta (POLH) and Checkpoint Clamp 145 Component (HUS1)) and local steroidogenic activity ((Estrogen Receptor 1(ESR1), Estrogen 146 Receptor 2(ESR2), Androgen Receptor (AR), Glucocorticoid Receptor (NR3C1), 147

Mineralocorticoid Receptor (NR3C2), Hydroxysteroid 11 Beta Dehydrogenase 1(HSD11B1), and Hydroxysteroid 11 Beta Dehydrogenase 2 (HSD11B2)) for determining transcript levels. Primer sequences were given in the supplementary Table 1. *GAPDH* and *ACTB* genes were used as housekeeping genes. All samples were analyzed in duplicate, and values were normalized using the $2^{-\Lambda\Lambda Ct}$ method [18–20].

153 Statistical Analysis

Data were collected using BioMark Real-Time PCR Analysis Software, the linear derivative 154 baseline correction method, and the auto global Ct threshold method. System-derived Ct 155 values of 999 and values larger than 26 were considered non-specific and beyond detection 156 limits and were therefore removed. Median Limit of detection (LOD)Ct values were 157 calculated across all arrays to impute missing values [21]. Data normalization was performed 158 using the $2^{-\Lambda\Lambda CT}$ method [20]. The compliance of the data to the normal distribution was 159 evaluated using a histogram, q-q graphs, and the Shapiro-Wilk test. Variance homogeneity 160 was evaluated using the Levene test. The one-way ANOVA test was used to compare the 161 differences between the 16 different transcripts levels of the lesional and non-lesional skin 162 tissues obtained from the patient group and skin tissues and blood samples obtained from the 163 164 healthy control group. The relationship between the quantitative data was evaluated using Spearman correlation analysis. Data were analyzed using Graphpad Prism (version 8.0.1) 165 166 software. P values <5% were considered statistically significant.

167 **RESULTS**

Twenty patients with chronic plaque psoriasis were included in the study. Of these patients, 10 (50%) were female patients. The control group consisted of 15 people, 8 (53.33%) healthy women and 7 (46.67%) healthy men. The mean ages of the patient and healthy control groups were 39.2 and 38.5, respectively. There is no statistically significant difference between the

groups in terms of age or gender (p > 0.05). The mean disease duration in the patient group was 14.4 years. The mean PASI was 15.8. The demographic characteristics of the patient and the control group are presented in Table 1.

175 Imbalance detected in the steroidogenic and DNA damage pathway in the lesional and

- 176 non-lesional skin tissue of patients with psoriasis
- 177 Transcripts levels were determined in skin biopsy and blood samples by qRT-PCR, the results178 are shown in Figures 1, 2 and Tables 2, 3.
- 179 The graphical summary of the heat map of transcripts in skin tissues is shown in Figure 3.
- Transcript levels of ESR1 (Estrogen Receptor 1), ESR2 (Estrogen Receptor 2), 180 HSD11B1(Hydroxysteroid 11 Beta Dehydrogenase), NR3C1(Glucocorticoid Receptor), 181 NR3C2 (Mineralocorticoid Receptor), POLH (DNA Polymerase Eta), and SMC1A 182 (Structural Maintenance Of Chromosomes 1A) in the lesional skin samples from psoriasis 183 patients were significantly decreased compared to the control group, while transcription levels 184 of AR (Androgen Receptor), TREX1 (Three Prime Repair Exonuclease 1), RAD1 (RAD1 185 Checkpoint DNA Exonuclease), and SSBP3 (Single-Stranded DNA Binding Protein 3) were 186 significantly increased in lesional skin samples of patients by compared to the control group 187 see Figure 1 and 2. 188

There was no significant difference between the groups in the transcript levels of *HSD11B2*(*Hydroxysteroid 11 Beta Dehydrogenase 2*), *TREX2 (Three Prime Repair Exonuclease 2*), *RAD18 (RAD 18 E3 Ubiquitin Protein Ligase), EXO1(Exonuclease 1),* and *HUS1(Checkpoint Clamp Component)* see Figure 1 and 2.

193 There was no difference in transcript levels in the non-lesional skin tissues and blood of 194 patients compared to a control group. Blood transcript profiles of the healthy control group 195 and patients with psoriasis are shown in Supplementary Table 2.

196 DISCUSSION

We have recently shown that in patients prone to psoriasis, genome integrity is compromised 197 with increased levels of TERRA and shortened telomere length in lesion tissue [22]. It is a 198 cause or a result? We do not know yet. We investigated novel pathways in the development of 199 psoriasis disease. The integrity of the epidermal barrier is very important for the regulation of 200 201 epidermal DNA synthesis [23]. Impaired local steroidogenic activity function causes disruption of the epidermal barrier of the skin as well as inflammatory and autoimmune 202 diseases [8]. Here, transcripts implicated in protecting epidermal barrier function and 203 204 regulating epidermal DNA synthesis have been reported in the lesional and non-lesional psoriasis skin. Overall, our results reveal that the local steroidogenic pathway was increased 205 with the androgen response, in contrast to the decreased estrogen response in psoriatic skin. 206

207 According to our results, the transcription levels of *Estrogen receptors (ESR1* and *ESR2)* were significantly decreased in the lesional skin samples compared to the control group and the 208 transcription levels of Androgen receptor (AR) were significantly increased in the lesional 209 skin samples compared to samples of non-lesional skin and the control group. This indicates 210 an increase in androgen and a decrease in estrogen response in psoriatic skin tissue. In 211 contrast to this, in blood samples, there was no difference between patient and control groups 212 213 in ESR1, ESR2, and AR transcript levels. Accordingly, the increased androgenic response is observed locally only in psoriatic skin. Dermal effects of estrogen include improved 214 development and function of the epidermal barrier and increased synthesis of collagen I and 215 216 III in keratinocytes [17]. Unlike the effects of estrogen, androgens trigger epidermal

hyperplasia and disrupt epidermal barrier function. Fluctuations in testosterone levels affect 217 218 epidermal barrier balance and barrier function improves in the absence of androgens [8]. Similarly, in a study with pregnant mice, exogenous estrogen given to pregnant mice 219 accelerated the development of the fetal epidermal barrier. In contrast, dihydro-testosterone 220 delays the formation of the epidermal barrier [24]. Our results indicate that the 221 androgen/estrogen balance in the skin of patients with psoriasis is impaired in the direction of 222 223 increased androgen response and decreased estrogen response, and disruption of the epidermal barrier is triggered in psoriatic skin, according to the literature. Thus, changes in 224 the hormonal balance of skin tissue have an etiological role in the development of psoriatic 225 226 lesions and trigger hyper-proliferation. It is now desirable to consider new treatment options that could adjust the levels of androgen and estrogen and their receptors in skin tissues, which 227 could improve skin recovery in patients. 228

Table 4 are summarized the function and the results shown here of the groups of transcripts. We report increased levels of three transcripts: *TREX1, RAD1* and *SSBP3* and decreased levels of *HSD11B1, POLH* and *SMC1A*, one of the largest cohesin subunits in lesion tissues.

232 These transcripts are involved in the various cellular processes and are listed below:

Local production of glucocorticoids occurs in different tissues, including lymphoid, brain and 233 234 skin. Recent studies have highlighted the importance of local glucocorticoid biosynthesis in maintaining skin homeostasis [13,25]. While Hydroxysteroid 11-Beta Dehydrogenase-235 1(HSD11B1) converts cortisone to its active form, cortisol, Hydroxysteroid 11-Beta 236 237 Dehydrogenase-2 (HSD11B2) converts cortisol to cortisone in an inactive form [26]. In our study, we found that HSD11B1 transcript levels decreased in the lesional skin tissue of 238 psoriasis patients compared to non-lesional and control group skin tissue, and there was no 239 240 change in HSD11B2 transcript levels. In one study, in vitro inhibition of HSD11B1

transcripts was shown to increase keratinocyte and fibroblast proliferation [27]. Thus, the decrease in *HSD11B1* transcript levels in the lesional skin of patients with psoriasis may be an indication that cortisol levels necessary to suppress inflammation and maintain skin homeostasis are not being produced. It can also support the literature on this topic by explaining the possible cause of keratinocyte hyper-proliferation in lesional tissue [8,27].

The glucocorticoid receptor (GR, NR3C1) and mineralocorticoid receptor (MR, NR3C2), 246 which provide adequate glucocorticoid and mineralocorticoid responses in tissue, are 247 members of the nuclear receptor superfamily. The roles of these receptors in inflammatory 248 skin diseases are currently being studied to develop new treatment options. Studies show that 249 a combined loss of epidermal GR and MR genes in knockout mouse models leads to acute 250 inflammation and psoriasis [13]. In a mouse study, impaired epidermal barrier, epidermal 251 hyperplasia, hyperkeratosis, parakeratosis, and abnormal keratinocyte differentiation were 252 found in keratinocyte-specific GR gene knockout mice. In recent years, unlike the effects of 253 MRs on other organs, its effects on the skin would be similar to those of GRs [28]. According 254 to our results, this could be due to the decrease in the transcript levels of the NR3C1 and 255 NR3C2 genes in the lesional tissue of the patients. At these levels glucocorticoids and 256 257 mineralocorticoids could not create an adequate response in the lesional tissues, therefore, inflammation could not be suppressed and abnormal hyper proliferation occurred in psoriatic 258 skin. 259

The Three Prime Repair Exonuclease enzymes (TREX1 and TREX2) are exonucleases responsible for DNA repair and degradation and act as DNA damage sensors. TREX1 separates cytoplasmic DNA into nucleotides that are not detected by Pattern Recognition Receptors (PRPs) to prevent the development of type 1 interferon (IFN-1) responses and thus autoimmune responses [29]. The enzyme TREX2 is also a 3'-5'exonuclease similar to TREX1. However, it is expressed in tissues such as skin, tongue, and esophagus. TREX2 breaks down

damaged nucleic acids and leads to activation of the inflammatory response [30]. Li et al.
reported that TREX2 transcript levels were significantly increased in psoriatic skin [31].
Manilis et al. found that loss of TREX2 eliminates inflammation in two psoriasis murine
models [32]. Here, our results reveal increased levels of *TREX1* transcript in the lesional skin
tissue compared to non-lesional tissue and the control group, whereas there was no difference
in *TREX2* transcript levels between the groups.

RAD1 Checkpoint DNA Exonuclease (RAD1), and RAD 18 E3 Ubiquitin Protein Ligase 272 273 (RAD18) are DNA damage sensors. RAD18 is a post-replicative enzyme that intervenes after DNA replication. The RAD1 gene encodes a component of a heterotrimeric cell cycle 274 checkpoint complex that is activated to halt cell cycle progression in response to DNA 275 damage [33]. An increase in *RAD1* transcripts indicates DNA damage and a decrease leads to 276 277 insufficient repair [34]. Here, we found that the RAD1 transcript levels increased in the lesional skin tissue compared to non-lesional tissue and the control group, and there was no 278 279 difference between groups in RAD18 transcript levels. The increase in RAD1 transcripts in the lesional tissue is an indicator of DNA damage in the skin cells of patients with psoriasis. Han 280 et al. found that keratinocytes isolated from RAD1 knockout mice showed significantly more 281 282 DNA double breaks and that these keratinocytes proliferated more slowly, and they suggested that this situation increased the susceptibility to the development of skin tumor [35]. 283 Consistent with the literature, our results indicate the role of DNA damage and RAD1 284 transcripts in the emergence of psoriatic skin phenotype. 285

286 Checkpoint Clamp Component (HUS1) and Exonuclease 1 (EXO1) are sensors responsible 287 for DNA damage repair. EXO1 is a 5'nuclease. In a study by Hibner et al. in 2014, they 288 evaluated the effect of Cyclosporin A (CsA) on normal human dermal fibroblasts through 289 DNA repair genes. They found that CsA suppresses the *EXO1* transcripts. In this case, they 290 suggested that CsA could cause tumor development by suppressing DNA repair genes [36].

CsA causes inhibition of cellular and humoral immune responses and has been a calcineurin inhibitor that has been used for many years in the treatment of severe psoriasis cases [37]. Patients who did not receive systemic treatment within the last four weeks were included in our study, and we found that there was no difference in the levels of *EXO1* and *HUS1* genes transcription in the tissues and blood samples from patients with psoriasis compared to the control group. Our results show that the *HUS1* and *EXO1* transcripts play no role in the formation of the psoriatic phenotype.

298 Eta DNA Polymerase (POLH) is a polymerase that is involved in DNA repair and lesion DNA synthesis. Increased POLH transcript levels are an indicator of increased DNA damage 299 and repair, and its transcripts decreased are an indicator of insufficient repair [38]. In a study 300 by Flanagan et al, it was found that although there was no POLH gene mutation in skin 301 biopsies taken from patients diagnosed with basal and squamous cell carcinoma, transcript 302 levels were decreased by compared to control skin tissue. We found that POLH transcript 303 levels were decreased in the lesional skin tissue, consistent with data from Flanagan et al. This 304 result indicates DNA damage and the role of POLH in psoriatic skin phenotype [39]. 305

Single Stranded DNA Binding Protein 3 (SSBP3) is a protein that binds to replication fork 306 307 strands and prevents the reformation of hydrogen bonds between the strands for DNA synthesis to function properly. Increased SSBP3 levels are a sign of increased DNA 308 309 replication and DNA damage repair in any tissue [40]. In addition, SSBP3 is related to 310 hydration of the skin, and its expression increases with the differentiation of keratinocyte [41]. Here our results indicate that SSBP3 transcripts increased in the lesional skin compared to 311 non-lesional skin and the control group. Our data suggest that SSBP3 is associated with both 312 313 increased DNA synthesis and damage due to excessive keratinocyte proliferation.

Cohesin is a DNA repair sensor which ensures the condensation of chromosomes during 314 315 mitosis and meiosis, and plays a critical role during DNA synthesis and in particular in the repair of double-stranded breaks in the DNA. Structural Maintenance of Chromosomes 1A 316 (SMC1A) is a protein that ensures proper separation of chromosomes and encodes the 317 structural component of cohesion [42]. Decreased levels of cohesion 318 lead to heterochromatinization and decreased expression of genes that act as regulators for cell 319 320 regeneration, thereby dysregulating epidermal differentiation [43,44]. However, the relationship between cohesin and skin diseases and its mode of expression in tissues have not 321 vet been revealed. According to our results, transcript levels of SMC1A, one of the largest 322 323 cohesin subunits, were decreased in the lesional skin tissue of patients with psoriasis leading to increased DNA damage and heterochromatinization and dysregulation of keratinocyte 324 differentiation in psoriatic skin. 325

Conclusion: Steroidogenic pathways are perturbed in the lesional tissue of patients with psoriasis and the damaged DNA cannot be repaired adequately. A higher androgen response triggers disruption of the epidermal barrier and perturb genome integrity due to increased DNA damage. We have previously shown that genome integrity is impaired in psoriasis [22] and suggest that this triggers the breakdown of the epidermal barrier and the development of lesions in patients with psoriasis.

- 332
- 333
- 334
- 335

336

	Psoriasis (Ps) (n=20)		Control (n=1	p voluo	
Sex	Female(n=10)	Male(n=10)	Female(n=8)	Male(n=7)	value
Age (year)	36.3±13.5	42.2±10.2	33.6±9.9	43.4±14.8	0.88
Disease duration (year)	43.4±14.8	13.5±9.7			
PASI	13.04±3.4	18.6±8.4			

Table 1. Demographic characteristics of the psoriasis patients and the control group

339	Table 2. Transcript profiles of the steroidogenic pathway, DNA damage and repair genes in
340	the blood of psoriasis patients (Ps) and the healthy control group.

	Genes	Ps	Control	P value
		(n=20)	(n=20)	
~	ESR1	0.9(0.7-1)	1(0.7-1.2)	0.420
ivity	ESR2	0.3(0.2-0.8)	0.3(0.2-2.6)	0.49
Act	AR	0.6(0.3-1.1)	1.1(0.6-1.9)	0.055
emic	NR3C1(GR)	0.6(0.3-1.1)	0.5(1.2-5)	0.828
idog	NR3C2(MR)	0.2(0.1-0.7)	1.3(0.2-17.8)	0.0570
teroi	HSD11B1	1.2(0.9-1.4)	1(0.3-4.9)	0.75
Ñ	HSD11B2	1.5(1.1-1.9)	1.2(0.6-2)	0.515
		1(0,0,1,2)	1 1 (0 0 1 4)	0 (22
. Ц	KADI	1(0.8-1.3)	1.1(0.9-1.4)	0.033
eba	RAD18	0.2(0.1-0.8)	0.9(0.1-2.6)	0.171
ыR	SMC1A	0.8(0.2-1.9)	1.6(0.2-8.1)	0.419
rs ar	EXO1	0.3(0.1-0.7)	0.2(0.1-1.8)	0.707
osua	HUS1	0.7(0.5-1.1)	0.7(0.2-2.9)	0.495
ge Si	TREX1	1.1(0.9-1.4)	1.1(0.8-1.5)	0.831
amag	TREX2	1.8(1.3-2.2)	1.2(0.8-1.4)	0.0688
A Da	SSBP3	0.9(0.7-1)	1(0.7-1.2)	0.419
DN	POLH	0.3(0.1-0.8)	0.8(0.1-2.3)	0.363
T1 1		1 1. /1 /	1 2 1 (1) D:	m 1 1 1 1

The data are expressed as median (1st and 3rd quartile). Different letters show the difference between groups

Table 3. The transcript profiles of the steroidogenic pathway, DNA damage and repair genes in the skin biopsies of psoriasis patients (Lesional, Non-lesional) and the healthy control group.

	Genes	Ps lesional tissue (n=20)	Ps non-lesional tissue (n=20)	Control tissue(n=15)	p value
	EGD1		0.5(0.2.0.c)ah	1(0 5 0 1)h	0.0070
>	ESRI	$0.3(0.1-0.7)^{a}$	$0.5(0.3-0.6)^{ab}$	$1(0.5-2.1)^{0}$	0.00/8
Ma	ESR2	$0.4(0.1-0.9)^{a}$	$0.8(0.3-1.3)^{ab}$	$1.1(0.4-2.8)^{b}$	0.0161
: Path	AR	2.2(0.9-7.6) ^a	0.4(0.2-2) ^b	0.5(0.3-1) ^b	0.0049
enic	NR3C1(GR)	0.5(0.2-1) ^a	1.2(0.6-2) ^b	1.2(0.7-1.7) ^b	0.0132
idog	NR3C2(MR)	0.2(0.04-0.3) ^a	0.5(0.3-1.5) ^b	0.8(0.5-2) ^b	<0.0001
cero	HSD11B1	$0.04(0.01-0.1)^{a}$	0.2(0.1-0.6) ^b	0.7(0.3-1.3) ^b	<0.0001
$\mathbf{\Sigma}$	HSD11B2	2.1(0.6-4.3)	1(0.7-2.3)	0.8(0.6-1.7)	0.3786
	RAD1	3.7(1.9-10.3) ^a	0.7(0.2-3.6) ^b	0.8(0.3-2.2) ^b	0.0013
nd	RAD18	0.5(0.1-1.1)	0.4(0.2-1.2)	0.9(0.7-1.6)	0.1349
rs a	SMCIA	$0.5(0.2-0.8)^{a}$	$0.8(0.6-1.2)^{ab}$	1.1(0.8-1.9)	0.008
losu	EXO1	1.1(0.4-2.4)	0.5(0.4-1.4)	1(0.8-1.4)	0.2002
e Sel Dairs	HUS1	1(0.5-2.3)	0.5(0.4-1.6)	1.1(0.7-1.5)	0.146
nag Rej	TREX1	$2.2(1.5-5)^{a}$	0.6(0.3-1.8) ^b	0.7(0.4-1.6) ^b	0.0067
Dar	TREX2	1.4(0.6-4)	1.6(0.7-2.1)	1.3(0.8-1.9)	0.6423
NA	SSBP3	3.4(1.4-6.6) ^a	0.4(0.1-2.1) ^b	0.6(0.2-2.2) ^b	0.005
A	POLH	0.4(0.2-1) ^a	0.8(0.4-1.8) ^{ab}	1.2(0.8-1.4) ^b	0.0208

The data are expressed as median (1st and 3rd quartile). Different letters show the difference between the groups.



Table 4. The function of the differentially expressed genes found to be associated with

psoriatic skin phenotype

Transcript Names	Gene Symbols	Chromosomal Localization	Gene Function	References
Estrogen Receptor 1	ESR1	6q25.1-q25.2	It is the alpha receptor of estrogen that controls many cellular processes, including the growth, differentiation, and function of the reproductive system. estrogen supports improved development and function of the epidermal barrier and increased synthesis of collagen.	[45][24][12] [6][14]
Estrogen Receptor 2	ESR2	14q23.2-q23.3	It is the beta receptor of estrogen that controls many cellular processes, including the growth, differentiation, and function of the reproductive system. Dermal effects of estrogen include improved development and function of the epidermal barrier and increased synthesis of collagen in skin	[45][24][12] [6][14]
Androgen Receptor	AR	Xq12	It is the receptor of androgens that triggers epidermal hyperplasia and disrupts the epidermal barrier function.	[45][9][12][6][24][14][4 6]
Glucocorticoid Receptor	NR3C1	5q31.3	Provide adequate glucocorticoid responses	[13][25][28] [45][8][14][46]
Mineralocorticoid Receptor	NR3C2	4q31	Provide adequate mineralocorticoid responses	[13][26][25] [45]
Hydroxysteroid 11 Beta Dehydrogenase 1	HSD11B1	1q32.2	Converts cortisone to cortisol in an active form	[45][13][8][14][26]
Hydroxysteroid 11 Beta Dehydrogenase 2	HSD11B2	16q22.1	Converts cortisol to cortisone in an inactive form	[45][13][8][14][26]
Structural Maintenance Of Chromosomes 1A	SMC1A	Xp11.22	Encodes the largest structural subcomponent of cohesin, which ensures proper segregation and condensation of chromosomes.	[43][44][42] [47]
Three Prime Repair Exonuclease 1	TREX1	3p21.31	3'-5'exonuclease, responsible for DNA repair and, act as a DNA damage sensor, breaks cytoplasmic DNA into nucleotides to prevent the development of autoimmune responses	[34][30][29] [48][32]
Three Prime Repair Exonuclease 2	TREX2	Xq28	3'-5'exonuclease, breaks down damaged nucleic acids and leads to activation of the inflammatory response.	[34][30][29] [48][32]
Single Stranded DNA Binding Protein 3	SSBP3	1p32.3	Binds to replication fork strands and prevents the reformation of hydrogen bonds between the strands for DNA synthesis to function properly. Increased levels are a sign of increased DNA replication and DNA damage repair. Related to the hydration of the skin, its expression increases in the differentiation process of keratinocytes.	[41]
RAD1 Checkpoint DNA Exonuclease	RAD1	5p13.2	DNA damage sensor, The post-replicative enzyme that intervenes after DNA replication, encodes a component of a heterotrimeric cell cycle checkpoint complex that is activated to halt cell cycle progression in response to	[35][33][49]

			DNA damage.	
RAD 18 E3 Ubiquitin	RAD18	3p25.3	DNA damage sensor, Required for the post-	[50][40][38]
Protein Ligase			replication repair of damaged DNA.	[44]
Exonuclease 1	EXO1	1q43	Encodes a protein with 5' to 3' exonuclease activity as	[40][47][33]
		<u>^</u>	well as an RNase H activity, Involved in mismatch	[38][51]
			repair and recombination.	
DNA Polymerase Eta	POLH	6p21.1	Involved in DNA repair and lesional DNA synthesis,	[39][52]
		_	the indicator of increased DNA damage and repair,	
Checkpoint Clamp	HUS1	7p12.3	DNA damage sensor, thought to be an early DNA	[35][40][34]
Component			damage checkpoint signal molecule.	

Table S1. The list of primer sequences used for in this study

Transcript Names and Symbols	Forward primer (5'- 3')	Reverse primer (5'- 3')
Estrogen Receptor 1 (ESR1)	GACAGGGAGCTGGTTCACA	GACCTGATCATGGAGGGTCAAA
Estrogen Receptor 2 (ESR2)	AGTCCCTGGTGTGAAGCAA	CGCAACGGTTCCCACTAAC
Androgen Receptor (AR)	CGCACCTGATGTGTGGTAC	GCCCATTTCGCTTTTGACAC
Glucocorticoid Receptor (NR3C1)	GCAGCAGTGAAATGGGCAAA	CAGTAGGGTCATTTGGTCATCCA
Mineralocorticoid Receptor (NR3C2)	CAGTAGGGTCATTTGGTCATCCA	CTGGCTTTTGAGGCCATCC
Hydroxysteroid 11 Beta Dehydrogenase 1 (HSD11B1)	GAAGCAGAGCAATGGAAGCA	TTGCAGAATAGGCAGCAACC
Hydroxysteroid 11 Beta Dehydrogenase 2 (HSD11B2	CGCGTGCTAGAGTTCACCAA	TCCGCATCAGCAACTACTTCA
Structural Maintenance Of Chromosomes 1A (SMC1A)	GCTGCCTTGGATAACACCAA	AGATGACGATGGCCTGGAA
Three Prime Repair Exonuclease 1 (TREX1)	ACCATCTGCTGTCACAACCA	TCTCTCCAAGGCTGGGACTA
Three Prime Repair Exonuclease 2 (TREX2)	GCCCAGAAGCCCAGGAA	CGGGGATAGCAAGTCCTCAA
Single Stranded DNA Binding Protein 3 (SSBP3)	AAAACATCACGTTGGGAGAAC	TTTCAGGAGCTGCACAGTAA
RAD1 Checkpoint DNA Exonuclease (RAD1)	ACGAGTGAAGTCCTACAAATTACCA	TGGGAACTTCCTGCATTTCCA
RAD 18 E3 Ubiquitin Protein Ligase (RAD18)	AACCGCATATTAGATGAACTGGTA	GCTGGTGACTCTAAAGCAAAC
Exonuclease 1 (EXO1)	ACTAGCCAAAGGTGAACCTAC	ACGAGAATAGGCTTGATCCC
DNA Polymerase Eta (POLH)	CAGGAACTAGAGGAGAGACTGAC	GTACACGAATGCTCACAACCA
Checkpoint Clamp Component (HUS1)	AAACACTTTCCCTGCCTCAC	TATGGGGATGTCATGGGTCAC

368		
369		
370		
371		
372	Refe	rences
373	1.	Roberson EDO, Bowcock AM. Psoriasis genetics: breaking the barrier Psoriasis: a
374		common inflammatory skin disease with a genetic component. 2011;26: 415-423.
375		doi:10.1016/j.tig.2010.06.006
376	2.	Stawczyk-Macieja M, Szczerkowska-Dobosz A, Rebała K, Purzycka-Bohdan D.
377		Genetic background of skin barrier dysfunction in the pathogenesis of psoriasis
378		vulgaris. Postep Dermatologii i Alergol. 2015;32: 123-126.
379		doi:10.5114/pdia.2014.44003
380	3.	Michalek IM, Loring B, John SM. A systematic review of worldwide epidemiology of
381		psoriasis. J Eur Acad Dermatology Venereol. 2017;31: 205-212.
382		doi:10.1111/jdv.13854
383	4.	Parisi R, Symmons DPM, Griffiths CEM, Ashcroft DM. Global epidemiology of
384		psoriasis: A systematic review of incidence and prevalence. J Invest Dermatol.
385		2013;133: 377-385. doi:10.1038/jid.2012.339
386	5.	Valdimarsson H, Bake BS, Jónsdótdr I, Fry L. Psoriasis: a disease of abnormal
387		Keratinocyte proliferation induced by T lymphocytes. Immunol Today. 1986;7: 256–
388		259. doi:10.1016/0167-5699(86)90005-8
389	6.	Zouboulis CC. The skin as an endocrine organ. Dermatoendocrinol. 2010:1: 250–252.
390		doi:10.4161/derm.1.5.9499
201	7	Walf P. Orion E. Buagao F. Buagao V. Abnormal anidermal barrier in the
391	1.	wolf R, Ohon E, Rubeco E, Rubeco V. Abhormar epidermar barrier in the
392		doi:10.1016/i.alindormatol.2011.08.022
292		doi.10.1010/j.ciiidciiiatoi.2011.08.022
394	8.	Terao M, Katayama I. Local cortisol/corticosterone activation in skin physiology and
395		pathology. J Dermatol Sci. 2016;84: 11-16. doi:10.1016/j.jdermsci.2016.06.014
396	9.	Kao JS, Garg A, Mao-Qiang M, Crumrine D, Ghadially R, Feingold KR, et al.
397		Testosterone perturbs epidermal permeability barrier homeostasis. J Invest Dermatol.

398 2001;116: 443–451. doi:10.1046/j.1523-1747.2001.01281.x

- Palmieri B, Vadalà M, Laurino C. Review of the molecular mechanisms in wound
 healing: new therapeutic targets? J Wound Care. 2017;26: 765–775.
 doi:10.12968/jowc.2017.26.12.765
- 402 11. Murakami K, Sawada A, Mori T, Sakuyama S, Tokudome Y. Effect of
 403 estrogen/progesterone ratio on the differentiation and the barrier function of epidermal
 404 keratinocyte and three-dimensional cultured human epidermis. Life Sci. 2022;293:
 405 120356. doi:10.1016/j.lfs.2022.120356
- Zouboulis CC, Chen WC, Thornton MJ, Qin K, Rosenfield R. Sexual hormones in
 human skin. Horm Metab Res. 2007;39: 85–95. doi:10.1055/s-2007-961807
- Sevilla LM, Pérez P. Roles of the glucocorticoid and mineralocorticoid receptors in
 skin pathophysiology. Int J Mol Sci. 2018;19. doi:10.3390/ijms19071906
- 14. Nikolakis G, Stratakis CA, Kanaki T, Slominski A, Zouboulis CC. Skin
 steroidogenesis in health and disease. Rev Endocr Metab Disord. 2016;17: 247–258.
 doi:10.1007/s11154-016-9390-z
- 413 15. Mehmetbeyoglu E, Kianmehr L, Borlu M, Yilmaz Z, Kılıc SB, Rajabi-Maham H, et al.
 414 Decrease in RNase HII and Accumulation of lncRNAs/DNA Hybrids: A Causal
- 415 Implication in Psoriasis? Biomolecules. 2022;12: 1–19. doi:10.3390/biom12030368
- Hawkes JE, Chan TC, Krueger JG. Psoriasis pathogenesis and the development of
 novel targeted immune therapies. J Allergy Clin Immunol. 2017;140: 645–653.
 doi:10.1016/j.jaci.2017.07.004
- Langley RG, Ellis CN. Evaluating psoriasis with psoriasis area and severity index,
 psoriasis global assessment, and lattice system physician's global assessment. J Am
 Acad Dermatol. 2004;51: 563–569. doi:10.1016/j.jaad.2004.04.012
- Taheri S, Karaca Z, Rassoulzadegan M, Mehmetbeyoglu E, Zararsiz G, Sener EF, et al.
 The Characterization of Sex Differences in Hypoglycemia-Induced Activation of HPA
 Axis on the Transcriptomic Level. Cell Mol Neurobiol. 2022;42: 1523–1542.
- 425 doi:10.1007/s10571-021-01043-0
- 426 19. Karaca Z, Taheri S, Firat ST, Borlu M, Zararsiz G, Mehmetbeyoglu E, et al. Molecular
 427 skin changes in Cushing syndrome and the effects of treatment. J Endocrinol Invest.

2020. doi:10.1007/s40618-020-01285-7 428 20. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time 429 guantitative PCR and the 2- $\Delta\Delta$ CT method. Methods. 2001;25: 402–408. 430 doi:10.1006/meth.2001.1262 431 21. Forootan A, Sjöback R, Björkman J, Sjögreen B, Linz L, Kubista M. Methods to 432 determine limit of detection and limit of quantification in quantitative real-time PCR 433 (qPCR). Biomol Detect Quantif. 2017;12: 1-6. doi:10.1016/j.bdg.2017.04.001 434 Mehmetbevoglu E, Kianmehr L, Borlu M, Yilmaz Z, Kılıc SB, Rajabi-Maham H, et al. 22. 435 Decrease in RNase HII and Accumulation of lncRNAs/DNA Hybrids: A Causal 436 437 Implication in Psoriasis? Biomolecules. 2022;12. doi:10.3390/BIOM12030368 23. Brettmann EA, de Guzman Strong C. Recent evolution of the human skin barrier. Exp 438 Dermatol. 2018;27: 859-866. doi:10.1111/exd.13689 439 24. Hanley K, Rassner U, Jiang Y, Vansomphone D, Crumrine D, Komüves L, et al. 440 441 Hormonal basis for the gender difference in epidermal barrier formation in the fetal rat: Acceleration by estrogen and delay by testosterone. J Clin Invest. 1996;97: 2576–2584. 442 doi:10.1172/JCI118706 443 25. 444 Boix J, Bigas J, Sevilla LM, Iacobone M, Citton M, Torresan F, et al. Primary aldosteronism patients show skin alterations and abnormal activation of glucocorticoid 445 receptor in keratinocytes. Sci Rep. 2017;7: 1-10. doi:10.1038/s41598-017-16216-5 446 Tomlinson JW, Stewart PM. Cortisol metabolism and the role of 11β-hydroxysteroid 26. 447 dehydrogenase. Best Pract Res Clin Endocrinol Metab. 2001;15: 61-78. 448 doi:10.1053/beem.2000.0119 449 Terao M, Itoi S, Murota H, Katayama I. Expression profiles of cortisol-inactivating 450 27. enzyme, 11^β-hydroxysteroid dehydrogenase-2, in human epidermal tumors and its role 451 in keratinocyte proliferation. Exp Dermatol. 2013;22: 98-101. doi:10.1111/exd.12075 452 Sevilla LM, Latorre V, Sanchis A, Pérez P. Epidermal inactivation of the 453 28. glucocorticoid receptor triggers skin barrier defects and cutaneous inflammation. J 454 Invest Dermatol. 2013;133: 361-370. doi:10.1038/jid.2012.281 455 29. Stetson DB, Ko JS, Heidmann T, Medzhitov R. Trex1 Prevents Cell-Intrinsic Initiation 456 of Autoimmunity. Cell. 2008;134: 587-598. doi:10.1016/j.cell.2008.06.032 457

458 459	30.	Mathers AR. TREX through Cutaneous Health and Disease. J Invest Dermatol. 2016;136: 2337–2339. doi:10.1016/j.jid.2016.06.628
460 461 462	31.	Li B, Tsoi LC, Swindell WR, Gudjonsson JE, Johnston A, Ding J, et al. sample : RNA- seq provides insights into disease mechanisms. 2015;134: 1828–1838. doi:10.1038/jid.2014.28.Transcriptome
463 464 465	32.	Manils J, Casas E, Viña-Vilaseca A, López-Cano M, Díez-Villanueva A, Gómez D, et al. The Exonuclease Trex2 Shapes Psoriatic Phenotype. J Invest Dermatol. 2016;136: 2345–2355. doi:10.1016/j.jid.2016.05.122
466 467 468	33.	McKinney JA, Wang G, Mukherjee A, Christensen L, Subramanian SHS, Zhao J, et al. Distinct DNA repair pathways cause genomic instability at alternative DNA structures. Nat Commun. 2020;11: 1–12. doi:10.1038/s41467-019-13878-9
469 470 471	34.	Wood R. Human DNA Repair Genes Database. Science (80-). 2001;291: 1284–1290. Available: https://www.mdanderson.org/documents/Labs/Wood-Laboratory/human- dna-repair-genes.html
472 473 474	35.	Han L, Hu Z, Liu Y, Wang X, Hopkins KM, Lieberman HB, et al. Mouse Rad1 deletion enhances susceptibility for skin tumor development. Mol Cancer. 2010;9: 1– 13. doi:10.1186/1476-4598-9-67
475 476 477	36.	Hibner G, Zajdel A, Wilczok A. Influence of cyclosporin a on expression pattern of genes associated with DNA repair in human dermal fibroblasts. Acta Pol Pharm - Drug Res. 2014;71: 956–961.
478 479 480	37.	Rosmarin DM, Lebwohl M, Elewski BE, Gottlieb AB. Cyclosporine and psoriasis: 2008 National Psoriasis Foundation* Consensus Conference. J Am Acad Dermatol. 2010;62: 838–853. doi:10.1016/j.jaad.2009.05.017
481 482 483	38.	Quinet A, Lerner LK, Martins DJ, Menck CFM. Filling gaps in translesion DNA synthesis in human cells. Mutat Res - Genet Toxicol Environ Mutagen. 2018;836: 127–142. doi:10.1016/j.mrgentox.2018.02.004
484 485 486 487	39.	Flanagan AM, Rafferty G, O'Neill A, Rynne L, Kelly J, McCann J, et al. The human POLH gene is not mutated, and is expressed in a cohort of patients with basal or squamous cell carcinoma of the skin. Int J Mol Med. 2007;19: 589–596. doi:10.3892/ijmm.19.4.589

488 489 490	40.	Ashton NW, Bolderson E, Cubeddu L, O'Byrne KJ, Richard DJ. Human single- stranded DNA binding proteins are essential for maintaining genomic stability. BMC Mol Biol. 2013;14: 1–20. doi:10.1186/1471-2199-14-9
491 492 493	41.	Choi MR, Shin JM, Shin YA, Chang YH, Chang MY, Lim CA, et al. Possible role of single stranded DNA binding protein 3 on skin hydration by regulating epidermal differentiation. Ann Dermatol. 2018;30: 432–440. doi:10.5021/ad.2018.30.4.432
494 495	42.	Musio A. The multiple facets of the SMC1A gene. Gene. 2020;743: 144612. doi:10.1016/j.gene.2020.144612
496 497 498	43.	Noutsou M, Li J, Ling J, Jones J, Wang Y, Chen Y, et al. The Cohesin Complex Is Necessary for Epidermal Progenitor Cell Function through Maintenance of Self- Renewal Genes. Cell Rep. 2017;20: 3005–3013. doi:10.1016/j.celrep.2017.09.003
499 500	44.	Litwin I, Pilarczyk E, Wysocki R. The Emerging Role of Cohesin in the DNA Damage Response. Genes (Basel). 2018;9: 581. doi:10.3390/genes9120581
501 502 503	45.	Slominski A, Zbytek B, Nikolakis G, Manna PR, Skobowiat C, Zmijewski M, et al. Steroidogenesis in the skin: Implications for local immune functions. J Steroid Biochem Mol Biol. 2013;137: 107–123. doi:10.1016/j.jsbmb.2013.02.006
504 505	46.	Alexopoulos A, Chrousos GP. Stress-related skin disorders. Rev Endocr Metab Disord. 2016;17: 295–304. doi:10.1007/s11154-016-9367-y
506 507	47.	Wang C, Zhao L, Lu S. Role of TERRA in the regulation of telomere length. Int J Biol Sci. 2015;11: 316–323. doi:10.7150/ijbs.10528
508 509 510 511	48.	Edqvist PHD, Fagerberg L, Hallström BM, Danielsson A, Edlund K, Uhlén M, et al. Expression of Human Skin-Specific Genes Defined by Transcriptomics and Antibody- Based Profiling. J Histochem Cytochem. 2015;63: 129–141. doi:10.1369/0022155414562646
512 513 514 515	49.	Carlomagno F, Burnet NG, Turesson I, Nyman J, Peacock JH, Dunning AM, et al. Comparison of DNA repair protein expression and activities between human fibroblast cell lines with different radiosensitivities. Int J Cancer. 2000;85: 845–849. doi:10.1002/(SICI)1097-0215(20000315)85:6<845::AID-IJC18>3.0.CO;2-C
516 517	50.	Volk LB, Cooper KL, Jiang T, Paffett ML, Hudson LG. Impacts of arsenic on Rad18 and translesion synthesis. Toxicol Appl Pharmacol. 2022;454: 116230.

- 518 doi:10.1016/j.taap.2022.116230
- 519 51. Kai M. Roles of RNA-binding proteins in DNA damage response. Int J Mol Sci.
- 520 2016;17: 1–9. doi:10.3390/ijms17030310
- 521 52. Wood RD, Mitchell M, Lindahl T. Human DNA repair genes, 2005. Mutat Res -
- 522 Fundam Mol Mech Mutagen. 2005;577: 275–283. doi:10.1016/j.mrfmmm.2005.03.007



Figure 1.

Figure 1. Transcription levels of genes involved in the local steroidogenic pathway in the lesional and non-lesional skin tissue samples from patients with psoriasis according to the control group.

When the transcript levels of local steroidogenic pathway genes in the lesional and non-lesional skin tissue samples from patients with psoriasis were compared to tissue samples from healthy volunteers, it was determined that the transcript levels of ESR1 (p: 0.0078) and ESR2 (p: 0.0161) genes were significantly decreased in the lesional tissue of patients with psoriasis compared to the control group. Transcription levels of *HSD11B1*(*p* <0.0001), *NR3C1* (*p*: 0.0132), and *NR3C2* (*p* <0.0001) were significantly decreased in the lesional tissue according to the non-lesional skin tissue and the control group. AR gene transcript levels were significantly increased in the lesional tissue compared to non-lesional tissue and the control group (p: 0.0049). There was no statistically significant difference between groups in HSD11B2 transcript levels (p: 0.3786).



Figure 2.

Figure 2. Transcription levels of DNA damage sensor and repairer genes in the lesional and non-lesional skin tissue samples from patients with psoriasis (Ps) according to control group.

When the transcript levels of the DNA damage sensor and damage genes were compared from tissue samples taken from healthy volunteers and lesional and nonlesional tissues from patients with psoriasis, the transcript levels of TREX1 (p: 0.0067), RAD1 (p: 0.0013), and SSBP3 (p: 0.005) were significantly increased in the lesional tissues compared to non-lesional tissues and control group. Transcription levels of POLH (p: 0.0208) and SMC1A (p: 0.008) genes were significantly decreased in the lesional tissue compared to tissue samples from the control group. There was no significant difference between the groups in the transcription levels of the TREX2, RAD18, EXO1, and HUS1 genes.



Figure 3. Heatmap graph of altered transcript profiles in skin biopsy samples from patients with psoriasis compared to control group (green color indicates genes with decreased transcript levels to control group, red color indicates genes with higher levels to control group). The transcription levels of ESR1, ESR2, NR3C1, NR3C2, HSD11B1, SMC1A, POLH genes were significantly decreased in the lesional tissue according to the control group, while the transcription levels of AR, TREX1, SSBP3 genes were significantly increased in the lesional tissue according to the control group. There was no significant difference between the groups in the transcription levels of the TREX2, RAD18, EXO1, and HUS1 genes.